BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
US Army

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,379,454

« Back to Dashboard

Summary for Patent: 4,379,454

Title: Dosage for coadministering drug and percutaneous absorption enhancer
Abstract:A dosage form that coadministers a drug and a percutaneous absorption enhancer to a defined area of the skin. The dosage form comprises a body that contains supplies of drug and enhancer and has a basal surface that contacts the area of skin and transmits the drug and enhancer to the area for absorption thereby. The drug is provided to the basal surface at a rate at least as great as the rate at which the skin is able to absorb the drug whereas the enhancer is via a rate controlling means at a substantially constant rate that increases the permeability of the treated area of skin to the drug to a level at which the drug is absorbed at a therapeutically effective rate.
Inventor(s): Campbell; Patricia S. (Palo Alto, CA), Chandrasekaran; Santosh K. (Palo Alto, CA)
Assignee: ALZA Corporation (Palo Alto, CA)
Application Number:06/235,068
Patent Claim Types:
see list of patent claims
Dosage form; Composition; Use;

No matches for this query

International Patent Family for Patent: 4,379,454

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia547007► Subscribe
Australia565178► Subscribe
Australia4502085► Subscribe
Australia7954582► Subscribe
Canada1166961► Subscribe
Canada1183085► Subscribe
Switzerland657055► Subscribe
Cyprus1400► Subscribe
Germany3205258► Subscribe
France2499859► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: